drugset / Trial / NCT03943875
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Phase 4
Completed
767 enrolled
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas · collab
RandomizedParallel-groupSingle-blindOther
Summary
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Timeline
- Start
- 2019-06-17
- Primary completion
- 2025-01-13
- Completion
- 2025-01-13
Publications
- Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2.
- Berenson AB, Panicker G, Unger ER, Rupp RE, Kuo YF. Immunogenicity of 2 or 3 Doses of 9vHPV Vaccine in U.S. Female Individuals 15 to 26 Years of Age. NEJM Evid. 2024 Feb;3(2):EVIDoa2300194. doi: 10.1056/EVIDoa2300194. Epub 2024 Jan 23.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil 9 | Vaccine | — | — |